Does cholesterol reduction with cholestyramine prevent coronary heart disease among individuals with prehypertension?

Abhijit V. Kshirsagar, Suma Vupputuri, David A. Shoham, Heejung Bang, Romulo E. Colindres, Ross J. Simpson

Research output: Contribution to journalArticle

1 Scopus citations


Background: There have been few treatment studies examining whether risk factor modification among individuals with prehypertension (120-139/80-89 mm Hg) is beneficial in reducing clinical measures of cardiovascular disease. Methods: We examined the effect of cholesterol reduction with cholestyramine on coronary heart disease (CHD) among prehypertensive men in a secondary analysis of the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT). 828 participants were randomized to placebo and 853 to cholestyramine. The two outcomes were definite CHD (i.e., death and/or definite non-fatal myocardial infarction (MI)), and any CHD (i.e., definite CHD death and/or definite non-fatal MI and/or suspect CHD death and/or suspect MI). Results: Cholestyramine use was associated with a 22% reduced risk of any CHD among prehypertensive men, Hazard ratio [HR] = 0.78; 95% Confidence Interval [CI]: 0.59 - 1.03, and absolute risk reduction of 3.2% (p = 0.05). The number needed to treat was 31. Conclusion: Intervention appears beneficial among prehypertensive individuals. Confirmatory studies specifically targeted to prehypertensive individuals for the prevention of CHD are warranted.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalClinical Research and Regulatory Affairs
Issue number3-4
StatePublished - Dec 1 2006
Externally publishedYes



  • Cholesterol Reduction
  • Cholesytramine
  • Prehypertension

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this